S&P 500 cuts losses as Nvidia climbs ahead of results
CAMBRIDGE, Mass. - Generation Bio Co. (NASDAQ:GBIO), currently trading at $0.52 with a market capitalization of $35 million, announced Friday it will implement a 1-for-10 reverse stock split of its common stock, effective July 21, 2025, with trading on a split-adjusted basis expected to begin July 22. According to InvestingPro data, the stock has seen a significant 35% return over the last week, though it remains 81% below its year-ago levels.
The reverse split, approved by stockholders at the company’s Annual Meeting on June 4, will reduce the number of outstanding shares from approximately 67.3 million to 6.7 million, while maintaining the same number of authorized shares and par value.
The primary goal of the split is to increase the company’s per-share market price to regain compliance with Nasdaq Global Select Market’s minimum bid price requirement for continued listing.
No fractional shares will be issued in the split. Stockholders who would otherwise receive fractional shares will receive cash payments instead. The company’s trading symbol will remain GBIO, though with a new CUSIP number (37148K 209).
Proportionate adjustments will be made to the number of shares available under the company’s equity incentive plans and to outstanding equity awards, according to the company’s statement.
Stockholders holding shares electronically are not required to take action to receive post-split shares, while those owning shares through banks or brokers will have their positions adjusted according to their respective institutions’ processes.
Generation Bio is a biotechnology company developing redosable therapeutics that reprogram T cells in vivo for patients with T cell-driven autoimmune diseases, using cell-targeted lipid nanoparticles to deliver small interfering RNA.
The announcement was made in a press release issued by the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.